Jiushishenkang Raises ￥100M in Series A Funding Round

In June 2020, Jiushishenkang closed Series A round of nearly 100 million yuan, led by Apricot Capital. Jiushishenkang is mainly engaged in the research and development of neurovascular intervention devices. The raised funds will be used to accelerate the clinical research of its new neurovascular product pipeline and the market promotion and industrialization of later products.

Founded in 2016, Jiushishenkang is an R&D-driven enterprise focusing on the R&D and commercialization of neurointerventional medical class 3 devices. To meet the clinical needs, the company has developed a number of neurointerventional products used in treatment for ischemia and hemorrhagic stroke. 

At present, Jiushishenkang has four pipelines of treatment for intracranial aneurysms, thrombectomy for acute ischemic stroke, stroke pathway, and stroke stenosis. The company has great potential and competitiveness in the industry in China.

Lu Weiyan, the founder of Jiusshenkang, once worked in leading companies MicroPort and Lepu Medical successively before starting his own business. He has participated in the R&D and industrialization of more than 20 cardiovascular and cerebrovascular interventional medical devices and successfully launched several products to the market. The company's core team members come from many leading medical device enterprises, with an average of more than 10 years’ experience in medical device R&D and industrialization.

Apricot Capital is an investment firm focused on investing in companies in the early and growth stages of the healthcare industry, including biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics, with AUM over 3 billion yuan.

Since its establishment, Apricot Capital has invested in excellent enterprises in the early and growth stage in the healthcare industry, covering fields such as biopharmaceuticals and medical devices. Portfolios include Junshi Biosciences, Akesobio, Sinomab Bioscience, Sinovent, MicroPort CardioFlow Medtech, Fountain Medical, Pharmcube, Ambrx, and many other companies.